mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2020-4-50-59mrj-1068Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL INVESTIGATIONSХарактеристика клинических, лабораторных и иммунологических проявлений у пациентов с болезнью Шёгрена, ассоциированной с антицентромерными антителамиCharacteristics of clinical, laboratory, and immunological manifestations in patients with anticentromere antibody-associated Sjögren's diseaseЧальцевБ. Д.ChaltsevB. D.

Россия, 115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522, Russia

bodya92@inbox.ruВасильевВ. И.VasilyevV. I.

Россия, 123056, Москва, Грузинский переулок, 3А

3A, Gruzinsky Lane, Moscow 123056, Russia

ПальшинаС. Г.PalshinaS. G.

Россия, 115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522, Russia

ТоргашинаА. В.TorgashinaA. V.

Россия, 115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522, Russia

СоколЕ. В.SokolE. V.

Россия, 115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522, Russia

ХванЮ. И.KhvanYu. I.

Россия, 115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522, Russia

РодионоваЕ. Б.RodionovaE. B.

Россия, 119021, Москва, ул. Тимура Фрунзе, 15/1

15/1, Timur Frunze St., Moscow 119021, Russia

СафоноваТ. Н.SafonovaT. N.

Россия, 119021, Москва, ул. Россолимо, 11А

11A, Rossolimo St., Moscow 119021; Russia

ЛапинС. В.LapinS. V.

Россия, 197022, Санкт-Петербург, ул. Льва Толстого, 6-8

6-8, Lev Tolstoy St., Saint Petersburg 197022, Russia

ТкаченкоО. Ю.TkachenkoO. Yu.

Россия, 197022, Санкт-Петербург, ул. Льва Толстого, 6-8

6-8, Lev Tolstoy St., Saint Petersburg 197022, Russia

МазингА. В.MazingA. V.

Россия, 197022, Санкт-Петербург, ул. Льва Толстого, 6-8

6-8, Lev Tolstoy St., Saint Petersburg 197022, Russia

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationКлиника МЕДСИРоссияMEDSI ClinicRussian FederationООО «Лечебный центр»РоссияOOO «Treatment Center»Russian FederationФГБНУ «Научно-исследовательский институт глазных болезней»РоссияResearch Institute of Eye DiseasesRussian FederationФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава РоссииРоссияAcad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaRussian Federation2020231120201445059Copyright © Чальцев Б.Д., Васильев В.И., Пальшина С.Г., Торгашина А.В., Сокол Е.В., Хван Ю.И., Родионова Е.Б., Сафонова Т.Н., Лапин С.В., Ткаченко О.Ю., Мазинг А.В., 20202020Чальцев Б.Д., Васильев В.И., Пальшина С.Г., Торгашина А.В., Сокол Е.В., Хван Ю.И., Родионова Е.Б., Сафонова Т.Н., Лапин С.В., Ткаченко О.Ю., Мазинг А.В.Chaltsev B.D., Vasilyev V.I., Palshina S.G., Torgashina A.V., Sokol E.V., Khvan Y.I., Rodionova E.B., Safonova T.N., Lapin S.V., Tkachenko O.Y., Mazing A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1068

Цель исследования – изучение клинических и лабораторных особенностей у пациентов с болезнью Шёгрена (БШ), позитивных по антицентромерным антителам (АЦА), а также чувствительности разных методов определения АЦА, разработка алгоритма дифференциальной диагностики у АЦА-позитивных пациентов.

Пациенты и методы

Пациенты и методы. В ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» под наблюдением находилось 136 высокопозитивных по АЦА пациентов. Для диагностики БШ использовались отечественные критерии 2001 г., системной склеродермии (ССД) – критерии ACR/EULAR 2013 г., первичного билиарного холангита (ПБХ)/эпителиита билиарных протоков в рамках БШ – рекомендации Американской ассоциации по изучению заболеваний печени, Российской гастроэнтерологической ассоциации и Российского общества по изучению печени. Диагностика лимфом осуществлялась на основании исследований биоптатов пораженных органов согласно классификации ВОЗ. БШ диагностирована у 119 пациентов, ССД – у 49 (у 37 в сочетании с БШ и у 12 – изолированная ССД), ПБХ/эпителиит билиарных протоков – у 23 (во всех случаях в сочетании с БШ и/или ССД), 5 пациентов были исключены из исследования. В дальнейший анализ вошел 131 АЦА-позитивный пациент. Больные были разделены на три группы: БШ (n=82, или 62,6%); БШ + ССД (n=37, или 28,24%); ССД (n=12, или 9,16%).

Результаты и обсуждение

Результаты и обсуждение. Аутоантитела к центромерному пептиду (CENP) A и CENP-B в одинаковых титрах выявлены у всех АЦА-позитивных пациентов независимо от диагноза. При сравнительном анализе трех групп пациентов статистически значимых различий в частоте лабораторных отклонений не выявлено. Характерные для классической БШ признаки – ревматоидный фактор (РФ), антитела к Ro и La, лейкопения, повышение СОЭ, гипергаммаглобулинемия, увеличение уровня IgG/IgA – обнаружены у незначительной части пациентов. Частота и выраженность железистых проявлений при БШ и БШ + ССД не различались. ПБХ/эпителиит билиарных протоков имелся у 17,5% АЦА-позитивных пациентов (в большинстве случаев позитивных по антимитохондриальным антителам), статистически значимых различий в его частоте между группами не обнаружено. Другие внежелезистые проявления при БШ и БШ + ССД выявлены у меньшего числа пациентов. Все проявления склеродермического спектра при ССД и БШ + ССД встречались чаще, чем при БШ. Легочная артериальная гипертензия не диагностирована ни у одного пациента из группы БШ. MALT-лимфомы обнаружены у 19 АЦА-позитивных пациентов. Они встречались только у пациентов с БШ, в группе ССД лимфом не было. MALT-лимфомы развивались в первые 10 лет после начала БШ. Трансформация MALT-лимфомы в диффузную В-клеточную крупноклеточную лимфому наблюдалась у 2 пациентов. Основными признаками лимфом у пациентов с БШ были: стойкое увеличение околоушных слюнных желез, снижение уровня С4-компонента комплемента, а также CD19+ клеток в периферической крови, криоглобулинемический васкулит, моноклональная секреция в сыворотке крови, лимфоидная инфильтрация малых слюнных желез >4 фокуса, а также тяжелое поражение слюнных и слезных желез.

Заключение

Заключение. БШ, ассоциированная с АЦА, является самостоятельным субтипом заболевания, отличающимся повышенным риском возникновения ССД, ПБХ и MALT-лимфом, низкой частотой характерных для классической БШ системных проявлений и лабораторных признаков. При БШ, независимо от выявляемого типа антител и наличия или отсутствия внежелезистых проявлений, прогрессирует поражение слюнных и слезных желез, что нередко приводит к развитию лимфом, поэтому терапия, способная предотвратить возникновение данного осложнения, должна быть инициирована сразу после установления диагноза БШ. Выявленные в настоящем исследовании признаки лимфопролиферации должны учитываться у всех АЦА-позитивных пациентов с БШ для ранней диагностики лимфоидных опухолей до назначения терапии. Приведен алгоритм дифференциальной диагностики при серопозитивности по АЦА. Определение аутоантител к CENP-A и CENP-B не позволяет осуществлять дифференциальную диагностику у АЦА-позитивных пациентов.

Objective

Objective: to study clinical and laboratory features in patients with anticentromere antibody (ACA)-positive SjЪgren's disease (SD), as well as the sensitivity of different methods for determination of ACA, and to elaborate an algorithm for differential diagnosis in ACA-positive patients.

Patients and methods

Patients and methods. The V.A. Nasonova Research Institute of Rheumatology followed up 136 patients who were highly positive for ACA. The investigators used the 2001 Russian criteria for the diagnosis for SD; the 2013 ACR/European League Against Rheumatism (EULAR) criteria for that of scleroderma systematica (SDS); the guidelines of the American Association for the Study of Liver Diseases, the Russian Gastroenterological Association, and the Russian Society for the Study of the Liver for that of primary biliary cholangitis (PBC)/biliary duct epitheliitis in the presence of SD. Lymphomas were diagnosed by biopsies of affected organs according to the WHO classification. SD was diagnosed in 119 patients; SDS in 49 cases (37 with SDS concurrent with SD and 12 with isolated SDS), PBC/biliary duct epitheliitis in 23 (all cases with PBC/biliary duct epitheliitis concurrent with SD and/or SDS); 5 patients were excluded from the investigation. Further analysis included 131 ACA-positive patients. The patients were divided into three groups: SD (n=82 or 62.6%); SD+SDS (n=37 or 28.24%); SDS (n=12 or 9.16%).

Results and discussion

Results and discussion. Autoantibodies to centromere peptide (CENP) A and CENP-B in the same titers were detected in all ACA-positive patients, regardless of diagnosis. Comparative analysis of three patient groups revealed no statistically significant differences in the frequency of laboratory deviations. The signs characteristic of classical SD (rheumatoid factor (RF)), anti-Ro and anti-La antibodies, leukopenia, higher ESR values, hypergammaglobulinemia, and elevated IgG/IgA levels) were found in a small proportion of patients. The frequency and severity of glandular manifestations did not differ in SD and SD + SDS. PBC/biliary duct epitheliitis was present in 17.5% of ACA-positive patients (in most antimitochondrial antibody-positive cases); no statistically significant differences in its frequency were found between the groups. Other extraglandular manifestations in SD and SD + SDS were identified in a smaller number of patients. All sclerodermic spectrum manifestations were more common in SD and SD + SDS than in BS. Pulmonary arterial hypertension was not diagnosed in any patient from the SD group. MALT lymphomas were detected in 19 ACA-positive patients. Those were present only in BS patients and absent in the SDS group. MALT lymphomas developed in the first 10 years after the onset of SD. The transformation of MALT lymphoma into diffuse large B-cell lymphoma was observed in 2 patients. The main signs of lymphomas in SD patients were persistent parotid salivary gland enlargement, decreased levels of complement C4 and peripheral blood CD19+ cells, as well as cryoglobulinemic vasculitis, serum monoclonal secretion, lymphoid infiltration in the minor salivary glands (a focus score of >4), and severe damage to the salivary and lacrimal glands.

Conclusion

Conclusion. ACA-associated SD is an independent disease subtype characterized by an increased risk for SDS, PBC, and MALT lymphomas and by a low frequency of the systemic manifestations and laboratory signs characteristic of classical SD. Regardless of the detected type of antibodies and the presence or absence of extraglandular manifestations, damage to the salivary and lacrimal glands progresses in SD, which often leads to lymphomas; therefore, the therapy that may prevent this complication should be initiated as soon as possible after SD diagnosis. The lymphoproliferation signs identified in this investigation should be taken into account in all ACA-positive patients with SD for the early diagnosis of lymphoid tumors before therapy is prescribed. An algorithm for differential diagnosis in seropositivity for ACA is presented. Determination of autoantibodies to CENP-A and CENP-B does not allow the differential diagnosis in ACA-positive patients.

антицентромерные антителаболезнь Шёгренасистемная склеродермияпервичный билиарный холангитлимпролиферативные заболеванияMALT-лимфомаanticentromere antibodiesSjögren's diseasescleroderma systematicaprimary biliary cholangitislymphoproliferative diseasesMALT lymphomaReferencesReksten TR, Jonsson MV. Sjogren's syndrome an update on epidemiology and current insights on pathophysiology. Oral Maxillofac Surg Clin North Am. 2014 Feb; 26(1):1-12. doi: 10.1016/j.coms.2013.09.002.Reksten TR, Jonsson MV. Sjogren's syndrome an update on epidemiology and current insights on pathophysiology. Oral Maxillofac Surg Clin North Am. 2014 Feb; 26(1):1-12. doi: 10.1016/j.coms.2013.09.002.Thomas E, Hay EM, Hajeer A, Silman AJ. Sjogren's syndrome: a community based study of prevalence and impact. Br J Rheumatol. 1998 Oct;37(10):1069-76. doi: 10.1093/rheumatology/37.10.1069.Thomas E, Hay EM, Hajeer A, Silman AJ. Sjogren's syndrome: a community based study of prevalence and impact. Br J Rheumatol. 1998 Oct;37(10):1069-76. doi: 10.1093/rheumatology/37.10.1069.Vivino FB, Bunya VY, Massaro-Giordano G, et al. Sjogren’s syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clin Immunol. 2019 Jun;203: 81-121. doi: 10.1016/j.clim.2019.04.009. Epub 2019 Apr 29.Vivino FB, Bunya VY, Massaro-Giordano G, et al. Sjogren’s syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clin Immunol. 2019 Jun;203: 81-121. doi: 10.1016/j.clim.2019.04.009. Epub 2019 Apr 29.Amador-Patarroyo MJ, Arbelaez JG, Ruben D, et al. Sjö gren’s syndrome at the crossroad of polyautoimmunity. J Autoimmun. 2012 Sep;39(3):199-205. doi: 10.1016/j.jaut. 2012.05.008. Epub 2012 Jun 30.Amador-Patarroyo MJ, Arbelaez JG, Ruben D, et al. Sjö gren’s syndrome at the crossroad of polyautoimmunity. J Autoimmun. 2012 Sep;39(3):199-205. doi: 10.1016/j.jaut. 2012.05.008. Epub 2012 Jun 30.Васильев ВИ. Болезнь Шёгрена: клинико-лабораторные, иммуноморфологические проявления и прогноз. Автореф. дисс. докт. мед. наук. Москва; 2007. 45 с.Vasil'ev VI. Sjogren's disease: clinical and laboratory, immunomorphological manifestations and prognosis. Autoref. diss. doct. med. sci. Moscow; 2007. 45 p.Brito-Zeron P, Ramos-Casals M, EULAR-SS task force group. Advances in the understanding and treatment of systemic complecations in Sjogren’s syndrome. Curr Opin Rheumatol. 2014 Sep;26(5):520-7. doi: 10.1097/BOR.0000000000000096.Brito-Zeron P, Ramos-Casals M, EULAR-SS task force group. Advances in the understanding and treatment of systemic complecations in Sjogren’s syndrome. Curr Opin Rheumatol. 2014 Sep;26(5):520-7. doi: 10.1097/BOR.0000000000000096.Gottenberg JE, Ravaud P, Puechal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjö gren syndrome: the JOQUER randomized clinical trial. JAMA. 2014 Jul 16;312(3):249-58. doi: 10.1001/jama.2014.7682.Gottenberg JE, Ravaud P, Puechal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjö gren syndrome: the JOQUER randomized clinical trial. JAMA. 2014 Jul 16;312(3):249-58. doi: 10.1001/jama.2014.7682.Fayyaz A, Kurien BT, Hal Scofield R. Autoantibodies in Sjö gren’s Syndrome. Rheum Dis Clin North Am. 2016 Aug;42(3): 419-34. doi: 10.1016/j.rdc.2016.03.002. Epub 2016 Jun 21.Fayyaz A, Kurien BT, Hal Scofield R. Autoantibodies in Sjö gren’s Syndrome. Rheum Dis Clin North Am. 2016 Aug;42(3): 419-34. doi: 10.1016/j.rdc.2016.03.002. Epub 2016 Jun 21.Nakamura H, Kawakami A, Hayashi T, et al. Anticentromere antibody-seropositive Sjö gren's syndrome differs from conventional subgroup in clinical and pathological study. BMC Musculoskelet Disord. 2010 Jul 1;11:140. doi: 10.1186/1471-2474-11-140.Nakamura H, Kawakami A, Hayashi T, et al. Anticentromere antibody-seropositive Sjö gren's syndrome differs from conventional subgroup in clinical and pathological study. BMC Musculoskelet Disord. 2010 Jul 1;11:140. doi: 10.1186/1471-2474-11-140.Baer AN, Medrano L, McAdams-DeMarco M, Gniadek TJ. Anticentromere antibodies are associated with more severe exocrine glandular dysfunction in Sjö gren’s syndrome: Analysis of the Sjö gren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2016 Oct;68(10):1554-9. doi: 10.1002/acr.22859. Epub 2016 Sep 16.Baer AN, Medrano L, McAdams-DeMarco M, Gniadek TJ. Anticentromere antibodies are associated with more severe exocrine glandular dysfunction in Sjö gren’s syndrome: Analysis of the Sjö gren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2016 Oct;68(10):1554-9. doi: 10.1002/acr.22859. Epub 2016 Sep 16.Tinazzi E, Patuzzo G, Lunardi C. Autoantigens and Autoantibodies in the Pathogenesis of Sjö gren’s Syndrome. In: Sjö gren’s Syndrome. Elsevier; 2016. P. 141-156.Tinazzi E, Patuzzo G, Lunardi C. Autoantigens and Autoantibodies in the Pathogenesis of Sjö gren’s Syndrome. In: Sjö gren’s Syndrome. Elsevier; 2016. P. 141-156.Vlachoyiannopoulos PG, Drosos AA, Wiik A, Moutsopoulos HM. Patients with anticenromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol. 1993 Apr;32(4):297-301. doi: 10.1093/rheumatology/32.4.297.Vlachoyiannopoulos PG, Drosos AA, Wiik A, Moutsopoulos HM. Patients with anticenromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol. 1993 Apr;32(4):297-301. doi: 10.1093/rheumatology/32.4.297.Villalta D, Imbastaro T, Di Giovanni S, et al. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev. 2012 Dec; 12(2):114-20. doi: 10.1016/j.autrev.2012.07.005Villalta D, Imbastaro T, Di Giovanni S, et al. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev. 2012 Dec; 12(2):114-20. doi: 10.1016/j.autrev.2012.07.005Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical and serologic features and survival in 1012 Italian patients. Medicine (Baltimore). 2002 Mar; 81(2):139-53. doi: 10.1097/00005792-200203000-00004.Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical and serologic features and survival in 1012 Italian patients. Medicine (Baltimore). 2002 Mar; 81(2):139-53. doi: 10.1097/00005792-200203000-00004.Ананьева ЛП, Александрова ЕН. Аутоантитела при системной склеродермии: спектр, клинические ассоциации и прогностическое значение. Научно-практическая ревматология. 2016;54(1):86-99.Anan'eva LP, Aleksandrova EN. Autoantibodies in systemic scleroderma: spectrum, clinical associations, and prognostic value. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2016;54(1):86-99. (In Russ.).Tanaka N, Muro Y, Suzuki Y, et al. Anticentromere antibody-positive primary Sjö gren's syndrome: Epitope analysis of a subset of anticentromere antibody-positive patients. Mod Rheumatol. 2017 Jan;27(1): 115-21. doi: 10.1080/14397595.2016.1176327. Epub 2016 May 10.Tanaka N, Muro Y, Suzuki Y, et al. Anticentromere antibody-positive primary Sjö gren's syndrome: Epitope analysis of a subset of anticentromere antibody-positive patients. Mod Rheumatol. 2017 Jan;27(1): 115-21. doi: 10.1080/14397595.2016.1176327. Epub 2016 May 10.Katano K, Kawano M, Koni I, et al. Clinical and laboratory features of anticentromere antibody positive primary Sjö gren's syndrome. J Rheumatol. 2001 Oct;28(10): 2238-44.Katano K, Kawano M, Koni I, et al. Clinical and laboratory features of anticentromere antibody positive primary Sjö gren's syndrome. J Rheumatol. 2001 Oct;28(10): 2238-44.Hudson M, Mahler M, Pope J, et al; Canadian Scleroderma Research Group. Clinical Correlates of CENP-A and CENP-B Antibodies in a Large Cohort of Patients with Systemic Sclerosis. J Rheumatol. 2012 Apr; 39(4):787-94. doi: 10.3899/rheum.111133.Hudson M, Mahler M, Pope J, et al; Canadian Scleroderma Research Group. Clinical Correlates of CENP-A and CENP-B Antibodies in a Large Cohort of Patients with Systemic Sclerosis. J Rheumatol. 2012 Apr; 39(4):787-94. doi: 10.3899/rheum.111133.Gelber AC, Pillemer SR, Baum BJ, et al. Distinct recognition of antibodies to centromere proteins in primary Sjogren’s syndrome compared with limited scleroderma. Ann Rheum Dis. 2006 Aug;65(8):1028-32. doi: 10.1136/ard.2005.046003. Epub 2006 Jan 13.Gelber AC, Pillemer SR, Baum BJ, et al. Distinct recognition of antibodies to centromere proteins in primary Sjogren’s syndrome compared with limited scleroderma. Ann Rheum Dis. 2006 Aug;65(8):1028-32. doi: 10.1136/ard.2005.046003. Epub 2006 Jan 13.Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с.Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p.Shiboski SC, Shiboski CH, Criswell LA, et al; Sjö gren’s International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology Classification Criteria for Sjö gren’s Syndrome: A Data-Driven, Expert Consensus Approach in the SICCA Cohort. Arthritis Care Res (Hoboken). 2012 Apr;64(4):475-87. doi: 10.1002/acr.21591.Shiboski SC, Shiboski CH, Criswell LA, et al; Sjö gren’s International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology Classification Criteria for Sjö gren’s Syndrome: A Data-Driven, Expert Consensus Approach in the SICCA Cohort. Arthritis Care Res (Hoboken). 2012 Apr;64(4):475-87. doi: 10.1002/acr.21591.Shiboski CH, Shiboski SC, le Seror R, et al; International Sjogren’s Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjogren’s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol. 2017 Jan;69(1): 35-45. doi: 10.1002/art.39859. Epub 2016 Oct 26.Shiboski CH, Shiboski SC, le Seror R, et al; International Sjogren’s Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjogren’s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol. 2017 Jan;69(1): 35-45. doi: 10.1002/art.39859. Epub 2016 Oct 26.Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013 Nov;65(11):2737-47. doi: 10.1002/art.38098. Epub 2013 Oct 3.Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013 Nov;65(11):2737-47. doi: 10.1002/art.38098. Epub 2013 Oct 3.Lindor KD, Bowlus CL, Boyer J, et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019 Jan; 69(1):394-419. doi: 10.1002/hep.30145. Epub 2018 Nov 6.Lindor KD, Bowlus CL, Boyer J, et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019 Jan; 69(1):394-419. doi: 10.1002/hep.30145. Epub 2018 Nov 6.Ивашкин ВТ, Широкова ЕН, Маевская МВ и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению холестаза. Российский журнал гастроэнтерологии гепатологии колопрактологии. 2015;2:41-57.Ivashkin VT, Shirokova YeN, Mayevskaya MV, et al. Clinical Guidelines of the Russian Gastroenterological Association and the Russian Society on Study of the Liver on Diagnostics and Treatment of Cholestasis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(2):41-57. (In Russ.).Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. IARC: Lyon; 2017. 523 p.Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. IARC: Lyon; 2017. 523 p.Tektonidou M, Kaskani E, Skopouli FN, Moutsopoulos HM. Microvascular abnormalities in Sjö gren's syndrome: nailfold capillaroscopy. Rheumatology (Oxford). 1999 Sep; 38(9):826-30. doi: 10.1093/rheumatology/38.9.826.Tektonidou M, Kaskani E, Skopouli FN, Moutsopoulos HM. Microvascular abnormalities in Sjö gren's syndrome: nailfold capillaroscopy. Rheumatology (Oxford). 1999 Sep; 38(9):826-30. doi: 10.1093/rheumatology/38.9.826.Baldini C, Mosca M, Della Rossa A, et al. Overlap of ACA-positive systemic sclerosis and Sjö gren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma. Clin Exp Rheumatol. Mar-Apr 2013;31(2):272-80. Epub 2013 Jan 18.Baldini C, Mosca M, Della Rossa A, et al. Overlap of ACA-positive systemic sclerosis and Sjö gren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma. Clin Exp Rheumatol. Mar-Apr 2013;31(2):272-80. Epub 2013 Jan 18.Gulati D, Kushner I, File E, Magrey M. Primary Sjogren’s syndrome with anticentromere antibodies – a clinically distinct subset. Clin Rheumatol. 2010 Jul;29(7):789-91. doi: 10.1007/s10067-009-1359-9. Epub 2010 Jan 19.Gulati D, Kushner I, File E, Magrey M. Primary Sjogren’s syndrome with anticentromere antibodies – a clinically distinct subset. Clin Rheumatol. 2010 Jul;29(7):789-91. doi: 10.1007/s10067-009-1359-9. Epub 2010 Jan 19.Retamozo S, Brito-Zeron P, RamosCasals M. Prognostic markers of lymphoma development in pSjS. Lupus. 2019 Jul;28(8): 923-36. doi: 10.1177/0961203319857132. Epub 2019 Jun 19.Retamozo S, Brito-Zeron P, RamosCasals M. Prognostic markers of lymphoma development in pSjS. Lupus. 2019 Jul;28(8): 923-36. doi: 10.1177/0961203319857132. Epub 2019 Jun 19.Sutcliffe N, Inanc M, Speight P, Isenberg D. Predictors of lymphoma development in primary Sjogrens syndrome. Semin Arthritis Rheum. 1998 Oct;28(2):80-7. doi: 10.1016/s0049-0172(98)80040-1.Sutcliffe N, Inanc M, Speight P, Isenberg D. Predictors of lymphoma development in primary Sjogrens syndrome. Semin Arthritis Rheum. 1998 Oct;28(2):80-7. doi: 10.1016/s0049-0172(98)80040-1.Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren’s syndrome. Arthritis Rheum. 2002 Mar;46(3): 741-7. doi: 10.1002/art.10221.Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren’s syndrome. Arthritis Rheum. 2002 Mar;46(3): 741-7. doi: 10.1002/art.10221.Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjogren’s syndrome: A cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006 Jun;65(6):796-803. doi: 10.1136/ard.2005.041186. Epub 2005 Nov 10.Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjogren’s syndrome: A cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006 Jun;65(6):796-803. doi: 10.1136/ard.2005.041186. Epub 2005 Nov 10.Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren’s syndrome. Arthritis Rheum. 1996 May;39(5):767-72. doi: 10.1002/art. 1780390508.Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren’s syndrome. Arthritis Rheum. 1996 May;39(5):767-72. doi: 10.1002/art. 1780390508.Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: Clinical and pathophysiologic aspects. Medicine (Baltimore). 2009 Sep;88(5):284-93. doi: 10.1097/MD.0b013e3181b76ab5.Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: Clinical and pathophysiologic aspects. Medicine (Baltimore). 2009 Sep;88(5):284-93. doi: 10.1097/MD.0b013e3181b76ab5.Solans-Laque R, Lopez-Hernandez A, Bosch-Gil JA, et al. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjogren’s syndrome. Semin Arthritis Rheum. 2011 Dec;41(3):415-23. doi: 10.1016/j.semarthrit.2011.04.006. Epub 2011 Jun 12..Solans-Laque R, Lopez-Hernandez A, Bosch-Gil JA, et al. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjogren’s syndrome. Semin Arthritis Rheum. 2011 Dec;41(3):415-23. doi: 10.1016/j.semarthrit.2011.04.006. Epub 2011 Jun 12..Baldini C, Pepe P, Luciano N, et al. A clinical prediction rule for lymphoma development in primary Sjö gren's syndrome. J Rheumatol. 2012 Apr;39(4):804-8. doi: 10.3899/jrheum.110754. Epub 2012 Feb 15.Baldini C, Pepe P, Luciano N, et al. A clinical prediction rule for lymphoma development in primary Sjö gren's syndrome. J Rheumatol. 2012 Apr;39(4):804-8. doi: 10.3899/jrheum.110754. Epub 2012 Feb 15.Johnsen SJ, Brun JG, G∅ransson LG, et al. Risk of non-Hodgkin’s lymphoma in primary Sjö gren’s syndrome: A populationbased study. Arthritis Care Res (Hoboken). 2013 May;65(5):816-21. doi: 10.1002/acr.21887.Johnsen SJ, Brun JG, G∅ransson LG, et al. Risk of non-Hodgkin’s lymphoma in primary Sjö gren’s syndrome: A populationbased study. Arthritis Care Res (Hoboken). 2013 May;65(5):816-21. doi: 10.1002/acr.21887.Quartuccio L, Isola M, Baldini C, et al. Biomarkers of lymphoma in Sjogren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: Results of a multicenter study. J Autoimmun. 2014 Jun;51: 75-80. doi: 10.1016/j.jaut.2013.10.002. Epub 2013 Nov 11.Quartuccio L, Isola M, Baldini C, et al. Biomarkers of lymphoma in Sjogren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: Results of a multicenter study. J Autoimmun. 2014 Jun;51: 75-80. doi: 10.1016/j.jaut.2013.10.002. Epub 2013 Nov 11.Risselada AP, Kruize AA, Bijlsma JW. Clinical features distinguishing lymphoma development in primary Sjogren’s syndrome: A retrospective cohort study. Semin Arthritis Rheum. 2013 Oct;43(2):171-7. doi: 10.1016/j.semarthrit.2013.03.001. Epub 2013 May 7.Risselada AP, Kruize AA, Bijlsma JW. Clinical features distinguishing lymphoma development in primary Sjogren’s syndrome: A retrospective cohort study. Semin Arthritis Rheum. 2013 Oct;43(2):171-7. doi: 10.1016/j.semarthrit.2013.03.001. Epub 2013 May 7.Fragkioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use. Medicine (Baltimore). 2016 Jun;95(25):e3766. doi: 10.1097/MD.0000000000003766.Fragkioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use. Medicine (Baltimore). 2016 Jun;95(25):e3766. doi: 10.1097/MD.0000000000003766.Mariette X, Criswell LA. Primary Sjö gren’s Syndrome. N Engl J Med. 2018 Mar 8;378(10):931-939. doi: 10.1056/NEJMcp1702514.Mariette X, Criswell LA. Primary Sjö gren’s Syndrome. N Engl J Med. 2018 Mar 8;378(10):931-939. doi: 10.1056/NEJMcp1702514.Chen X, Wu H, Wei W. Advances in the diagnosis and treatment of Sjogren’s syndrome. Clin Rheumatol. 2018 Jul;37(7): 1743-1749. doi: 10.1007/s10067-018-4153-8. Epub 2018 May 26.Chen X, Wu H, Wei W. Advances in the diagnosis and treatment of Sjogren’s syndrome. Clin Rheumatol. 2018 Jul;37(7): 1743-1749. doi: 10.1007/s10067-018-4153-8. Epub 2018 May 26.Stefanski AL, Tomiak C, Pleyer U, et al. The Diagnosis and Treatment of Sjö gren’s Syndrome. Dtsch Arztebl Int. 2017 May 26; 114(20):354-361. doi: 10.3238/arztebl. 2017.0354.Stefanski AL, Tomiak C, Pleyer U, et al. The Diagnosis and Treatment of Sjö gren’s Syndrome. Dtsch Arztebl Int. 2017 May 26; 114(20):354-361. doi: 10.3238/arztebl. 2017.0354.

The authors declare that there are no conflicts of interest present.